Loading clinical trials...
Loading clinical trials...
A Phase 2 Study of Bevacizumab for Chronic Bleeding and Iron Deficiency Anemia in Hereditary Hemorrhagic Telangiectasia (Trial Using Systemic Bevacizumab to Treat HHT, TrUST-HHT)
Conditions
Interventions
Bevacizumab (Avastin®)
Locations
1
United States
Massachusetts General Hospital
Boston, Massachusetts, United States
Start Date
November 23, 2020
Primary Completion Date
April 1, 2026
Completion Date
February 1, 2027
Last Updated
March 27, 2026
NCT07445347
NCT04874558
NCT04646356
NCT03397004
NCT05550376
NCT01752049
Lead Sponsor
Hanny Al-Samkari, MD
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions